BMY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 19.72%. Bristol-Myers Squibb's return on equity of 32.01% beat Gilead Sciences's return on equity of 32.29%.

Bristol-Myers Squibb has a consensus price target of $57.20, signalling upside risk potential of 22.02%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 17.19%. Given that Bristol-Myers Squibb has higher upside potential than Gilead Sciences, analysts believe Bristol-Myers Squibb is more attractive than Gilead Sciences.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Gilead Sciences offers a yield of 3.16% to investors and pays a quarterly dividend of $0.79 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Bristol-Myers Squibb's net income of $2.5B is higher than Gilead Sciences's net income of $1.3B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.56x while Gilead Sciences's PE ratio is 20.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 4.31x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 50.24%. Bristol-Myers Squibb's return on equity of 32.01% beat Johnson & Johnson's return on equity of 30.18%.

Bristol-Myers Squibb has a consensus price target of $57.20, signalling upside risk potential of 22.02%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 8.2%. Given that Bristol-Myers Squibb has higher upside potential than Johnson & Johnson, analysts believe Bristol-Myers Squibb is more attractive than Johnson & Johnson.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Johnson & Johnson offers a yield of 3.15% to investors and pays a quarterly dividend of $1.24 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Bristol-Myers Squibb's net income of $2.5B is lower than Johnson & Johnson's net income of $11B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.56x while Johnson & Johnson's PE ratio is 17.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 4.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 21.68%. Bristol-Myers Squibb's return on equity of 32.01% beat Eli Lilly and's return on equity of 78.25%.

Bristol-Myers Squibb has a consensus price target of $57.20, signalling upside risk potential of 22.02%. On the other hand Eli Lilly and has an analysts' consensus of $981.63 which suggests that it could grow by 26.38%. Given that Eli Lilly and has higher upside potential than Bristol-Myers Squibb, analysts believe Eli Lilly and is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.50 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Bristol-Myers Squibb's net income of $2.5B is lower than Eli Lilly and's net income of $2.8B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.56x while Eli Lilly and's PE ratio is 63.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 14.32x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 32.71%. Bristol-Myers Squibb's return on equity of 32.01% beat Merck &'s return on equity of 39.02%.

Bristol-Myers Squibb has a consensus price target of $57.20, signalling upside risk potential of 22.02%. On the other hand Merck & has an analysts' consensus of $105.02 which suggests that it could grow by 32.74%. Given that Merck & has higher upside potential than Bristol-Myers Squibb, analysts believe Merck & is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Merck & offers a yield of 3.99% to investors and pays a quarterly dividend of $0.81 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are smaller than Merck & quarterly revenues of $15.5B. Bristol-Myers Squibb's net income of $2.5B is lower than Merck &'s net income of $5.1B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.56x while Merck &'s PE ratio is 11.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 3.14x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.